CELC · Celcuity Inc. · Exempt Offerings
$56.48
+0.88 (+1.58%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$2.73B
Shares
49.13M
Volume · Nov 19
86.28K
Avg daily vol (3M)
1.23M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2025-09-23 | Amendment | Biotechnology | $352,700,000 | $130,000,000 | 06b |
| 2024-10-15 | Amendment | Biotechnology | $50,000,000 | $50,000,000 | 06b |
| 2024-06-28 | Amendment | Biotechnology | $184,500,000 | $100,000,000 | 06b |
| 2024-04-25 | Amendment | Biotechnology | $75,375,000 | $35,000,000 | 06b |
| 2023-11-27 | Amendment | Biotechnology | $2,975,746 | $2,597,057 | 06b |
| 2023-11-27 | Amendment | Biotechnology | $6,612,667 | $5,930,006 | 06b |
| 2023-10-26 | New | Biotechnology | $50,000,000 | $50,000,000 | 06b |
| 2023-05-02 | Amendment | Biotechnology | $75,375,000 | $35,000,000 | 06b |
| 2022-11-28 | Amendment | Biotechnology | $6,612,667 | $5,930,006 | 06b |
| 2022-11-28 | Amendment | Biotechnology | $2,975,746 | $2,597,057 | 06b |
| 2022-05-26 | New | Biotechnology | $155,999,997 | $99,999,998 | 06b |
| 2022-04-08 | Amendment | Biotechnology | $25,625,000 | $15,000,000 | 06b |
| 2021-11-22 | Amendment | Biotechnology | $2,975,746 | $2,597,057 | 06b |
| 2021-11-22 | Amendment | Biotechnology | $6,612,667 | $5,930,006 | 06b |
| 2021-04-14 | New | Biotechnology | $5,000,000 | $5,000,000 | 06b |
| 2021-04-14 | New | Biotechnology | $25,625,000 | $15,000,000 | 06b |
| 2020-11-02 | Amendment | Biotechnology | $6,612,667 | $5,930,006 | 06b |
| 2020-11-02 | Amendment | Biotechnology | $2,975,746 | $2,597,057 | 06b |
Showing 1–18 of 18 filings
Key facts
CIK
1603454
CUSIP
15102K100
13F (30d)
273 filings
259 filers
Visit website
Investor relations